Amazing Biotech Stock: CURE Pharmaceutical (OTCQB: CURR) is a Developer of Patented Drug Delivery Tech to Enhance the Effectiveness for a Range of Important Medications
November 19, 2020 (Viz Release) – – CURE Pharmaceutical (OTCQB: CURR) COMPLETES $10 Million Financing to Strongly Expand Global Marketing and Drive Revenue Returns
– FDA-Registered, NSF(R) and cGMP-Certified Manufacturing Facility.
– Patented Techniques Improve Efficacy, Safety, and Patient Experience.
– $10 Million Financing Deal Completed to Expand Marketing Worldwide.
– Wholly Owned Subsidiary SeraLabs(R) Introduces Nutri-Strips(TM), a new Oral Thin Film Strip Technology for Sleep Aid and Immunity Applications.
CURE Pharmaceutical (OTCQB: CURR) is a fully integrated and progressive drug delivery company. The CURR team has extensive experience formulating and manufacturing OTC products, pharmaceuticals, and veterinary medications placing quality and service as its top priorities, earning the trust and respect of customers worldwide.
CURR is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate-release and controlled-release drug delivery technologies designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. CURR delivery technologies include CUREfilm(R), an advanced oral thin film; and CUREdrops(TM), an emulsion technology that can be incorporated into different dosage forms (film, tincture, beverages, etc.), among others. The CURR proprietary clinical pipeline includes CUREfilm(R) Blue (sildenafil to treat erectile dysfunction), and CUREfilm(R) Canna (THC and CBD).
As a vertically integrated company, CURR operates a 25,000 square foot, FDA-registered, NSF(R) and cGMP-certified manufacturing facility enabling it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURR currently has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
– CURE Pharmaceutical Closes $10 Million Financing
On November 2nd CURR announced it had received the first tranche of $4 million in a committed financing of $10 million, after original issue discounts, through the issuance of convertible notes. Axiom Capital Management, Inc. acted as the sole placement agent in the transaction. CURR may repay the obligations of the notes in cash only, or the notes may be converted upon election of the investor at a fixed price of $1.32 per share subject to certain adjustments.
This financing will enable CURR to achieve a number of key company goals and sets the stage for making 2021 a breakout year for the company. CURR has already set in motion the steps needed for progress in two key areas: driving strong sales growth of newly acquired Sera Labs, and advancing its clinical pharmaceutical pipeline, particularly the lead clinical development program for the CURR high value ED treatment, CUREfilm Blue(TM).
– Wholly Owned Subsidiary SeraLabs(R) Introduces Nutri-Strips(TM), a Revolutionary Oral Thin Film Strip Technology
On October 29th CURR announced its wholly owned subsidiary Sera Labs was launching the Nutri-Strips brand with a multi-channel advertising and marketing strategy beginning initially with “Sleep A.S.A.P.(TM),” which offers a fast-acting, drug-free solution to America’s sleep problem.
CURR has developed a broad platform of formulations that offer targeted dosing including patented and advanced oral thin film strip technology, which Sera Labs has branded RAD3 — for Rapid Activation Delivery and which it is using to deliver novel vitamins and supplements. CURR Nutri-Strips are administered and activate directly on the tongue, allowing for rapid delivery. This means there is no need for water, chewing or struggling to swallow pills. The strips are formulated by utilizing proprietary organic polymers that trap the active ingredients in a liquid matrix which is then cured into the Nutri-Strips.
Millions of American’s have trouble sleeping; according to BCC research, with $52 billion being spent annually on sleep products with Sleep A.S.A.P. as the drug free alternative to sleeping pills. CURR scientists developed this proprietary formulation for sleep by blending five of the most powerful sleep ingredients into one dose to help you get to sleep and stay asleep.
CURR is also launching ImmunD3(TM) to supercharge the immune system (with a once-a-week 40,000IU dose of Vitamin D3), EnergY(TM) to enhance performance and mental focus, and RecoverB(TM) for electrolyte and muscle recovery. Additionally, three exciting new line extensions are set to launch in the first quarter of 2021. The brand has already begun an aggressive Q4 digital, print and Sirius radio campaign and will have a national TV broadcast campaign starting Q1 2021 to create the world’s most impactful oral thin strip nutraceutical brand.
The company’s recent acquisition by of Sera Labs was fueled largely to help commercialize Nutri-Strip. CURR management expects to see a steep sales trajectory as of a result of its extensive marketing, brand penetration and education campaigns. Now, more than ever consumers are hyper focused on their health and pocketbook and Nutri-Strips solves this problem by offering maximum potency of essential vitamins and supplements while not breaking the bank.
The CURR Nutri-Strip line is non-addictive, has no side effects and is created by top formulation scientists. Each strip is hermetically sealed in airtight, grab-and-go packaging to eliminate chemical and structural breakdown and provide superior potency. Most recently, Nutri-Strip was touted at a prominent virtual industry trade show for buyers in retail as the most innovative line in the supplement category seen in years.
DISCLAIMER: CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CA is NOT affiliated in any manner with any company mentioned herein. CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CA has been compensated $400.00 for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.